✨
AI Summary
- ENV-294, an oral Rac2 modulator, showed promise in a phase 1b study for atopic dermatitis.
- The investigational treatment significantly reduced EASI scores in moderate to severe cases.
- Improvements in atopic dermatitis continued even after the treatment period ended.
Guests on This Episode
LK
Leon Kircik
2 podcast appearances